Abbott Won’t Shrink From Competitor Merck’s Cordaptive
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s niacin/laropiprant combination will compete against Abbott’s Niaspan after it is approved by FDA.
You may also be interested in...
TriLipix Exceeding Abbott’s Expectations Shortly After Launch, Execs Say
Shortly after the launch of TriLipix, Abbott is seeing patients switch from its established fenofibrate TriCor to the next-generation drug- a welcoming sign for the firm, given that TriCor is expected to face generics in 2011
TriLipix Exceeding Abbott’s Expectations Shortly After Launch, Execs Say
Shortly after the launch of TriLipix, Abbott is seeing patients switch from its established fenofibrate TriCor to the next-generation drug- a welcoming sign for the firm, given that TriCor is expected to face generics in 2011
Merck: Second “Not Approvable” Letter In Two Days – This Time, Cordaptive
FDA nixes name, too, for anti-cholesterol niacin/laropiprant combo.